Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2014

View Archived Issues

New evidence demonstrating that Huntington's disease is a four-repeat tauopathy

Identification of SARMs that can be administered transdermally

Medigene advances TAB immunotherapy platform through new collaborations and funding

Asfotase alfa shows benefit in phase II trials in pediatric patients with hypophosphatasia

Circle Pharma receives funding to develop cell permeable macrocyclic peptide therapeutics

Charcot-Marie-Tooth Association forms alliance with Genzyme

Mutation identified in a patient with hyperlysinemia

MIS-416 treatment enhances systemic negative regulators of inflammation in patient plasma

Critical Path Institute receives second grant for advancing tuberculosis treatments

Genocea receives grant for malaria vaccine discovery

Navidea awarded NIH grant for evaluation of Lymphoseek in cervical cancer

Access Pharmaceuticals licenses plasma fractionation process and renames company

Results from second pivotal study of Rayaldee for secondary hyperparathyroidism

Selective monoacylglycerol lipase inhibitor improves experimental MS

Roche discloses novel triazole compounds for HCV infection

New antibiotic-steroid codrugs disclosed by Allergan

FDA approves T2Candida Panel and T2Dx Instrument for detection of Candida

Gilead reports phase III data for elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine

FDA grants orphan drug designation to MabVax Therapeutics' neuroblastoma vaccine

Inovio and GeneOne plan phase I trial of Ebola vaccine candidate

FDA approves Spiriva Respimat inhalation spray for maintenance treatment of COPD

Acorda Therapeutics to acquire Civitas Therapeutics

FDA approves Humira for pediatric Crohn's disease

Servier returns rights to pan-HDAC inhibitors to Pharmacyclics

GliaCure initiates phase I trial of Alzheimer's disease candidate

FDA grants orphan drug status to IMM-101 for pancreatic cancer

Japanese approval for fomepizole to treat ethylene glycol and methanol poisonings

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...